Puma Biotechnology | PBYI - Capital Ordinário





Capital Ordinário Alterar Data
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Daiichi Sankyo JPY 1.85B 9K 2025-12
Exelixis USD 253.7M 8.78M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Incyte USD 199.95M 1.49M 2026-03
MacroGenics USD 63.56M 241K 2026-03
Moderna USD 391M 2M 2025-09
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sarepta Therapeutics USD 105.57M 607K 2026-03
Takeda JPY 1.58B 241K 2026-03
TG Therapeutics USD 155.31M 95K 2025-12
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12
Vertex Pharmaceuticals USD 254.2M 200K 2026-03